Tian Chen, Zhang Yizhuo
Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China.
Onco Targets Ther. 2016 Sep 13;9:5659-5661. doi: 10.2147/OTT.S110572. eCollection 2016.
Most primary stomach lymphomas are now recognized to originate from B-cell. Primary gastric anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALCL) as shown in this case is very rare.
A 59-year-old man presented with a 1-month history of epigastric pain. Computed tomography showed a tumor in the stomach with perigastric lymphadenopathy. Biopsy of the tumor with gastroendoscopy showed ALCL. Bone marrow aspiration and trephine biopsy showed no infiltration. A diagnosis of primary gastric ALK-negative ALCL was made. The patient was first treated with four cycles of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) regimen, but his condition did not show improvement. Then he was treated with two cycles of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate and cytarabine (Hyper-CVAD/MA) regimen. In spite of these treatments, he still died of disease progression.
The prognosis of ALK-negative ALCLs is usually worse than ALK-positive ALCLs. In this case, the patient was not responsive to a multidrug chemotherapy with CHOP and Hyper-CVAD/MA.
目前大多数原发性胃淋巴瘤被认为起源于B细胞。如本病例所示的原发性胃间变性淋巴瘤激酶(ALK)阴性间变性大细胞淋巴瘤(ALCL)非常罕见。
一名59岁男性,有1个月的上腹部疼痛病史。计算机断层扫描显示胃内有肿瘤伴胃周淋巴结肿大。胃镜检查对肿瘤进行活检显示为ALCL。骨髓穿刺和活检未见浸润。诊断为原发性胃ALK阴性ALCL。患者首先接受了四个周期的环磷酰胺、阿霉素、长春新碱、泼尼松(CHOP)方案治疗,但病情未见改善。然后他接受了两个周期的超分割环磷酰胺、长春新碱、阿霉素和地塞米松/甲氨蝶呤及阿糖胞苷(Hyper-CVAD/MA)方案治疗。尽管进行了这些治疗,他仍死于疾病进展。
ALK阴性ALCL的预后通常比ALK阳性ALCL差。在本病例中,患者对CHOP和Hyper-CVAD/MA的多药化疗无反应。